SCHEMBL2911007

SCHEMBL2911007

O=C(O)Oc1ccc([N+](=O)[O-])cc1CC1COCO1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
KCNJ1 P48048 1/20 0.37
CTSB P07858 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
CYP1A2 P05177 1/20 0.36
ALDH1A1 P00352 3/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 1/20 0.35
PKM P14618 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
NPBWR1 P48145 1/20 0.34
MCHR1 Q99705 1/20 0.34
PTPN2 P17706 1/20 0.34
PTPN1 P18031 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2911008 1.00 PRMT5 (0.38) PRMT5WDR77KCNJ1CTSBPTGDR2
SCHEMBL28688584 0.80 MAPT (0.42) PTGDR2CYP1A2ALDH1A1NPSR1L3MBTL1
SCHEMBL2021778 0.79 PRMT5 (0.48) PRMT5WDR77CTSBCYP1A2ALDH1A1
SCHEMBL2021776 0.79 PRMT5 (0.48) PRMT5WDR77CTSBCYP1A2ALDH1A1
SCHEMBL31374520 0.77 ALDH1A1 (0.40) PTGDR2CYP1A2ALDH1A1NPSR1L3MBTL1
SCHEMBL8586072 0.77 KDM4E (0.37) ALDH1A1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL32662599 0.77 CYP1A2 (0.46) PTGDR2CYP1A2ALDH1A1L3MBTL1MEN1
SCHEMBL2916438 0.76 HSP90AA1 (0.40) KCNJ1PTGDR2CYP1A2ALDH1A1NPSR1
SCHEMBL2916434 0.76 HSP90AA1 (0.40) KCNJ1PTGDR2CYP1A2ALDH1A1NPSR1
SCHEMBL28102381 0.76 ALDH1A1 (0.46) PTGDR2CYP1A2ALDH1A1L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1637528-B1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease VERTEX PHARMA (US) 2010-09-01 EP disclosed
EP-1637528-A1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2006-03-22 EP disclosed
CN-1110491-C Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease VERTEX PHARMA (US) 2003-06-04 CN disclosed
EP-0833826-B1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease VERTEX PHARMA (US) 2002-01-23 EP disclosed
EP-1136479-A1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2001-09-26 EP disclosed
US-6127372-A FOR TREATMENT OR PREVENTION OF VIRAL DISEASES, ESPECIALLY AIDS OR HIV VERTEX PHARMACEUTICALS, INCORPORATED (US) 2000-10-03 US disclosed
US-5990155-A VIRICIDES AGAINST THE HIV-1 AND HIV-2 VIRUSES; REVERSE TRANSCRIPTASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 1999-11-23 US disclosed
EP-0749421-B1 SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS VERTEX PHARMA (US) 1999-09-15 EP disclosed
CN-1184474-A Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease VERTEX PHARMA (US) 1998-06-10 CN disclosed
EP-0833826-A1 OXYGENATED-HETEROCYCLE CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 1998-04-08 EP disclosed
US-5691372-A Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 1997-11-25 US disclosed
WO-1996033187-A1 OXYGENATED-HETEROCYCLE CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1996-10-24 WO disclosed
WO-1995024385-A1 SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 1995-09-14 WO disclosed